The Food and Drug Administration (FDA) approved the drug romosozumab (Evenity) for osteoporosis in April 2019. Evenity joins two other anabolic agents (teriparatide [Forteo] and abaloparatide [Tymlos]), which treat the bone-thinning disease osteoporosis by stimulating bone formation. Evenity has a new mechanism of action. In head-to-head studies, Evenity increased bone mass more than Forteo. The anabolics differ from other osteoporosis drugs, which work by preventing bone from breaking down. (Bone undergoes a natural cycle of breaking down and building back up.) In one of the studies that led to the approval of Evenity, the drug lowered the risk for a spine fracture by 73 percent compared with placebo after one year. Evenity is approved for postmenopausal women with osteoporosis who are at high risk for a bone fracture. Evenity is given as a monthly injection for 12 months by a healthcare provider in a doctor's office.